Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2012, Article ID 368528, 8 pages
http://dx.doi.org/10.1155/2012/368528
Clinical Study

Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer

1Department of Radiotherapy, Ghent University Hospital, 9000 Ghent, Belgium
2Department of Urology, Ghent University Hospital, 9000 Ghent, Belgium
3Department of Radiology, Ghent University Hospital, 9000 Ghent, Belgium

Received 7 June 2011; Accepted 21 September 2011

Academic Editor: Martin Spahn

Copyright © 2012 Valérie Fonteyne et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. Patients with high-risk prostate cancer (PC) can be treated with high-dose intensity-modulated radiotherapy (IMRT) and long-term androgen deprivation (AD). In this paper we report on (i) late toxicity and (ii) biochemical (bRFS) and clinical relapse-free survival (cRFS) of this combined treatment. Methods. 126 patients with high-risk PC (T3-4 or PSA >20 ng/mL or Gleason 8–10) and ≥24 months of followup were treated with high-dose IMRT and AD. Late toxicity was recorded. Biochemical relapse was defined as PSA nadir +2 ng/mL. Clinical relapse was defined as local failure or metastases. Results. The incidence of late grade 3 gastrointestinal and genitourinary toxicity was 2 and 6%, respectively. Five-year bRFS and cRFS were 73% and 86% respectively. AD was a significant predictor of bRFS and cRFS . Conclusion. High-dose IMRT and AD for high-risk PC offers excellent biochemical and clinical control with low toxicity.